Christopher Hart

Creyon Bio, Inc. is a pre-clinical stage drug development company based in San Diego, CA. The company is focused on developing precision oligonucleotide-based medicines (OBMs) such as ASOs, siRNAs, guide RNAs, RNA editing guides, mRNAs, and aptamers. Creyon Bio uses a data-first approach to generate powerful datasets and develop machine learning models to uncover the engineering principles that make precision OBMs possible for patient populations of all sizes. The CEO of the company is Christopher E Hart.

Creyon Bio, Inc. is a pre-clinical stage drug development company based in San Diego, CA. The company is focused on developing precision oligonucleotide-based medicines (OBMs) such as ASOs, siRNAs, guide RNAs, RNA editing guides, mRNAs, and aptamers. Creyon Bio uses a data-first approach to generate powerful datasets and develop machine learning models to uncover the engineering principles that make precision OBMs possible for patient populations of all sizes. The CEO of the company is Christopher E Hart.

Creyon Bio, Inc. is a pre-clinical stage drug development company based in San Diego, CA. The company is focused on developing precision oligonucleotide-based medicines (OBMs) such as ASOs, siRNAs, guide RNAs, RNA editing guides, mRNAs, and aptamers. Creyon Bio uses a data-first approach to generate powerful datasets and develop machine learning models to uncover the engineering principles that make precision OBMs possible for patient populations of all sizes. The CEO of the company is Christopher E Hart.